You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mutation Positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    NSCLC Trial in Shanghai (IN10018, Furmonertinib)

    Recruiting
    • NSCLC
    • Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 8, 2023

    NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Mar 23, 2023

    Advanced Cancers, Solid Tumors Trial in Houston (Pazopanib, Everolimus)

    Active, not recruiting
    • Advanced Cancers
    • Solid Tumors
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 16, 2022

    Real-world Data of Afatinib Treatment in First-line Setting and

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Tokyo, Japan
      Nippon Boehringer Ingelheim Co., Ltd.
    Jan 9, 2023

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 13, 2022

    Solid Tumors, KRAS Mutation Trial in Chiba, Kashiwa, Tokyo, Chuo-ku, Tokyo, Koto-ku (BI 3011441)

    Completed
    • Solid Tumors, KRAS Mutation
    • BI 3011441
    • Chiba, Kashiwa, Japan
    • +2 more
    Nov 11, 2022

    EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among

    Recruiting
    • Lung Cancer
    • Kuala Lumpur, Malaysia
    • +2 more
    Nov 21, 2022

    NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Maastricht, Limburg, Netherlands
    • +4 more
    Nov 7, 2022

    NSCLC Trial in Changsha (Furmonertinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer hospital
    May 19, 2022

    Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • EGFR Gene Mutation
    • Shang'ai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 27, 2022

    Non Small Cell Lung Cancer Trial in Seoul (Neoadjuvant lazertinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Neoadjuvant lazertinib
    • Seoul, Korea, Republic of
      Konkuk University Medical Center
    Jul 20, 2022

    Lung Adenocarcinoma Stage III Trial in Shanghai (HS-10296 (Almonertinib))

    Recruiting
    • Lung Adenocarcinoma Stage III
    • HS-10296 (Almonertinib)
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 17, 2022

    Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • BRAF V600E Mutation Positive
    • Encorafenib Oral Capsule + Cetuximab
    • (no location specified)
    Jan 30, 2023

    Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

    Recruiting
    • Non-Small Cell Lung Carcinoma
    • Capmatinib 150 mg
    • Capmatinib 200 mg
    • Guwahati, Assam, India
    • +7 more
    Dec 19, 2022

    PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

    Recruiting
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Mar 9, 2022

      Melanoma, Adjuvant Trial (Dabrafenib and Trametinib, Dabrafenib, Trametinib)

      Available
      • Melanoma
      • Adjuvant
      • Dabrafenib and Trametinib
      • +2 more
      • (no location specified)
      Mar 1, 2022

      Lung Cancer, NSCLC, PD-L1 Gene Mutation Trial in Detroit (Durvalumab, Carboplatin, Pemetrexed)

      Withdrawn
      • Lung Cancer
      • +3 more
      • Detroit, Michigan
        Henry Ford Health System
      Feb 15, 2022

      NSCLC Trial in Spain, United Kingdom, United States (Lazertinib)

      Completed
      • Carcinoma, Non-Small-Cell Lung
      • Duarte, California
      • +8 more
      Jan 31, 2023

      Metastatic NSCLC Trial in Shanghai (Gentuximab)

      Recruiting
      • Metastatic Non-Small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Chest Hospital
      Jan 24, 2022

      Non-Small Cell Lung Carcinoma Trial in Duarte, Stanford, Nashville (drug, biological, other)

      Terminated
      • Non-Small Cell Lung Carcinoma
      • Duarte, California
      • +2 more
      Apr 6, 2022

      Lung Cancer Trial in Seoul (Osimertinib 80 MG)

      Suspended
      • Lung Cancer
      • Osimertinib 80 MG
      • Seoul, Korea, Republic of
        Samsung medical center
      Jan 13, 2022

      Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

      Terminated
      Has Results
      • Leukemia, Myeloid, Acute
      • Denver, Colorado
      • +4 more
      May 10, 2022